Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab

BACKGROUND: We hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse. METHODS: Plasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome. RESULTS: The median OSM in biochemical responders was 86 (69–148) pg/mL compared with 166 (74–1766) pg/mL in nonresponders (P = 0.03). Plasma OSM > 143.5 pg/mL was 71% sensitive and 78% specific for biochemical nonresponse (area under the curve 0.71). Early biochemical nonremission was also associated with an elevated neutrophil CD64 expression (odds ratio 8.9, P = 0.011). CONCLUSIONS: Elevated preinfliximab plasma OSM and nCD64 surface expression were both associated with poor biochemical outcomes.